Cryoport (CYRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chair, with directors, executive officers, CFO, and independent auditors present.
Agenda and rules of conduct made available on the virtual meeting site and investor relations website.
Board and executive committee updates
Six directors nominated for election to serve a one-year term expiring at the 2027 Annual Meeting.
Shareholder proposals
Four management proposals presented: election of directors, ratification of independent auditor, advisory approval of executive compensation, and amendment to the equity incentive plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cryoport
- 16% revenue growth and 70% CGT trial share highlight strong momentum and global expansion.CYRX
Corporate presentation3 Jun 2026 - FY2025 revenue rose 12% to $176.2M, with margin expansion and strong CGT market growth.CYRX
Q4 202512 May 2026 - Q1 2026 revenue up 16–16.5%, guidance raised, and profitability expected in H2 2026.CYRX
Q1 20265 May 2026 - Strong revenue growth, digital transformation, and key governance votes mark this year's proxy.CYRX
Proxy filing23 Apr 2026 - Key votes include director elections, auditor ratification, and equity plan share increase.CYRX
Proxy filing23 Apr 2026 - Q3 2024 saw service growth, margin gains, and reaffirmed guidance despite product softness.CYRX
Q3 202414 Mar 2026 - Q2 2024 revenue hit $57.6M, with 51% cell/gene therapy growth and a $63.8M impairment loss.CYRX
Q2 202414 Mar 2026 - 2024 revenue hit $228.4M, Q4 margin rose to 45.8%, and 2025 guidance is $240–$250M with EBITDA positivity.CYRX
Q4 202414 Mar 2026 - Q1 2025 revenue up 10%; DHL deal and CRYOPDP sale to boost global reach and liquidity.CYRX
Q1 202514 Mar 2026